Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC

Radiation Oncology trials using PET with FDG uptake among NSCLC patients

Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC